389 related articles for article (PubMed ID: 34340125)
1. Potential inhibitors of the main protease of SARS-CoV-2 and modulators of arachidonic acid pathway: Non-steroidal anti-inflammatory drugs against COVID-19.
Sisakht M; Solhjoo A; Mahmoodzadeh A; Fathalipour M; Kabiri M; Sakhteman A
Comput Biol Med; 2021 Sep; 136():104686. PubMed ID: 34340125
[TBL] [Abstract][Full Text] [Related]
2. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
3. Computational Insights on the Potential of Some NSAIDs for Treating COVID-19: Priority Set and Lead Optimization.
Abo Elmaaty A; Hamed MIA; Ismail MI; B Elkaeed E; S Abulkhair H; Khattab M; Al-Karmalawy AA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34205704
[TBL] [Abstract][Full Text] [Related]
4. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
5. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
[TBL] [Abstract][Full Text] [Related]
6. In Silico Evaluation of Prospective Anti-COVID-19 Drug Candidates as Potential SARS-CoV-2 Main Protease Inhibitors.
Ibrahim MAA; Abdelrahman AHM; Allemailem KS; Almatroudi A; Moustafa MF; Hegazy MF
Protein J; 2021 Jun; 40(3):296-309. PubMed ID: 33387249
[TBL] [Abstract][Full Text] [Related]
7.
Rudrapal M; Issahaku AR; Agoni C; Bendale AR; Nagar A; Soliman MES; Lokwani D
J Biomol Struct Dyn; 2022; 40(20):10437-10453. PubMed ID: 34182889
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and Identification of Novel Potential Molecules Against COVID-19 Main Protease Through Structure-Guided Virtual Screening Approach.
El Bakri Y; Anouar EH; Ahmad S; Nassar AA; Taha ML; Mague JT; El Ghayati L; Essassi EM
Appl Biochem Biotechnol; 2021 Nov; 193(11):3602-3623. PubMed ID: 34324152
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
Abdizadeh R; Hadizadeh F; Abdizadeh T
J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
[TBL] [Abstract][Full Text] [Related]
10. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
11. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
[TBL] [Abstract][Full Text] [Related]
12. Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
de Azevedo Junior WF; Bitencourt-Ferreira G; Godoy JR; Adriano HMA; Dos Santos Bezerra WA; Dos Santos Soares AM
Curr Med Chem; 2021; 28(37):7614-7633. PubMed ID: 33781188
[TBL] [Abstract][Full Text] [Related]
13. Chloropyridinyl Esters of Nonsteroidal Anti-Inflammatory Agents and Related Derivatives as Potent SARS-CoV-2 3CL Protease Inhibitors.
Ghosh AK; Shahabi D; Yadav M; Kovela S; Anson BJ; Lendy EK; Bonham C; Sirohi D; Brito-Sierra CA; Hattori SI; Kuhn R; Mitsuya H; Mesecar AD
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641337
[TBL] [Abstract][Full Text] [Related]
14. Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach.
Bhowmick S; Saha A; Osman SM; Alasmary FA; Almutairi TM; Islam MA
Mol Divers; 2021 Aug; 25(3):1979-1997. PubMed ID: 33844135
[TBL] [Abstract][Full Text] [Related]
15. Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.
Gogoi B; Chowdhury P; Goswami N; Gogoi N; Naiya T; Chetia P; Mahanta S; Chetia D; Tanti B; Borah P; Handique PJ
Mol Divers; 2021 Aug; 25(3):1963-1977. PubMed ID: 33856591
[TBL] [Abstract][Full Text] [Related]
16.
Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
[TBL] [Abstract][Full Text] [Related]
17. Repurposing simeprevir, calpain inhibitor IV and a cathepsin F inhibitor against SARS-CoV-2 and insights into their interactions with M
J A; Francis D; C S S; K G A; C S; Variyar EJ
J Biomol Struct Dyn; 2022 Jan; 40(1):325-336. PubMed ID: 32873185
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis and biological evaluation of novel 3C-like protease inhibitors as lead compounds against SARS-CoV-2.
Yan Y; Liu H; Wu D; Gu Z; Guo W; Yao H; Lin K; Li X
Future Med Chem; 2024; 16(9):887-903. PubMed ID: 38618977
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationship (SAR) and molecular dynamics study of withaferin-A fragment derivatives as potential therapeutic lead against main protease (M
Ghosh A; Chakraborty M; Chandra A; Alam MP
J Mol Model; 2021 Feb; 27(3):97. PubMed ID: 33641023
[TBL] [Abstract][Full Text] [Related]
20.
Maurya AK; Mishra N
J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
